Overview

A class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws.  The Elanco class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023, and June 26, 2024, both dates inclusive (the “Class Period”).  Investors have until December 6, 2024, to seek appointment as lead plaintiff in the Elanco class action lawsuit.

Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals.  The Company is developing, inter alia, Zenrelia, a “safe, highly effective, and convenient” once-daily oral Janus kinase (“JAK”) inhibitor for canine dermatology, and Credelio Quattro, a broad spectrum parasiticide product for dogs.

In November 2023, Elanco set a timeline for the U.S. approval of both Zenrelia and Credelio Quattro in the first half of 2024.  Then, in May 2024, Elanco set a timeline for the U.S. approval and commercial launch of Zenrelia in the third quarter of 2024, as well as the U.S. approval of Credelio Quattro in the third quarter of 2024 with a commercial launch set for the fourth quarter of 2024.

The Elanco class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company’s business and/or financial prospects were overstated; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Elanco securities between November 7, 2023, and June 26, 2024, both dates inclusive and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as a lead plaintiff in the Elanco class action lawsuit is December 6, 2024.